Clinical and Experimental Nephrology

, Volume 15, Issue 1, pp 30–33 | Cite as

Renal preservation effect of ubiquinol, the reduced form of coenzyme Q10

  • Akira Ishikawa
  • Hiroo Kawarazaki
  • Katsuyuki Ando
  • Megumi Fujita
  • Toshiro Fujita
  • Yukio Homma
Original Article



The aim of this study was to evaluate the renal preservation effect of ubiquinol, the reduced form of coenzyme Q10 (CoQ10).


Three-week-old heminephrectomized male Sprague–Dawley rats were divided into three groups (10 animals each): diet with normal (0.3%) salt, high (8%) salt, and high salt plus 600 mg/kg body weight/day of ubiquinol, for 4 weeks. Systolic blood pressure (SBP), urinary albumin (u-alb), superoxide anion generation (lucigenin chemiluminescence) and ubiquinol levels in renal tissues were examined.


Salt loading increased SBP (111.0 ± 3.6 vs. 169.4 ± 14.3 mmHg, p < 0.01) and u-alb (43.8 ± 28.0 vs. 2528.7 ± 1379.0 µg/day, p < 0.02). These changes were associated with stimulation of superoxide generation in the kidney (866.3 ± 102.8 vs. 2721.4 ± 973.3 RLU/g kidney, p < 0.01). However, ubiquinol decreased SBP (143.9 ± 29.0 mmHg, p < 0.05), u-alb (256.1 ± 122.1 µg/day, p < 0.02), and renal superoxide production (877.8 ± 195.6 RLU/g kidney, p < 0.01), associated with an increase in renal ubiquinol levels.


Ubiquinol, the reduced form of CoQ10, effectively ameliorates renal function, probably due to its antioxidant effect. Thus, ubiquinol may be a candidate for the treatment of patients with kidney disease.


Ubiquinol Ubiquinone Oxidative stress Urinary albumin Chronic renal disease 


  1. 1.
    Lysaght J. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002;13(Suppl):S37–40.PubMedGoogle Scholar
  2. 2.
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.Google Scholar
  3. 3.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMedGoogle Scholar
  4. 4.
    Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, Luno J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int. 2008;74(Suppl):S4–9.CrossRefGoogle Scholar
  5. 5.
    Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438–46.CrossRefPubMedGoogle Scholar
  6. 6.
    Liu F, Wei CC, Wu SJ, Chenier I, Zhang SL, Filep JG, et al. Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. Kidney Int. 2009;75:156–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Manning RD Jr, Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol. 2005;25:311–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Hosoe K, Kitano M, Kishida H, Kubo H, Fujii K, Kitahara M. Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol. 2007;47:19–28.CrossRefPubMedGoogle Scholar
  9. 9.
    Carlström M, Sällström J, Skøtt O, Larsson E, Persson AE. Uninephrectomy in young age or chronic salt loading causes salt-sensitive hypertension in adult rats. Hypertension. 2007;49:1342–50.CrossRefPubMedGoogle Scholar
  10. 10.
    Kitano M, Watanabe D, Oda S, Kubo H, Kishida H, Fujii K, et al. Subchronic oral toxicity of ubiquinol in rats and dogs. Int J Toxicol. 2008;27:189–215.CrossRefPubMedGoogle Scholar
  11. 11.
    Matsui H, Shimosawa T, Uetake Y, Wang H, Ogura S, Kaneko T, et al. Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension. 2006;48:225–31.CrossRefPubMedGoogle Scholar
  12. 12.
    Kishimoto C, Tomioka N, Nakayama Y, Miyamoto M. Anti-oxidant effects of coenzyme Q10 on experimental viral myocarditis in mice. J Cardiovasc Pharmacol. 2003;42:588–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Bello RI, Gómez-Díaz C, Burón MI, Alcaín FJ, Navas P, Villalba JM. Enhanced anti-oxidant protection of liver membranes in long-lived rats fed on a coenzyme Q10-supplemented diet. Exp Gerontol. 2005;40:694–706.CrossRefPubMedGoogle Scholar
  14. 14.
    Mohr D, Umeda Y, Redgrave TG, Stocker R. Antioxidant defenses in rat intestine and mesenteric lymph. Redox Rep. 1999;4:79–87.CrossRefPubMedGoogle Scholar
  15. 15.
    Lim SC, Tan HH, Goh SK, Subramanian T, Sum CF, Tan IK, et al. Oxidative burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q10. Diabet Med. 2006;23:1344–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Yamamoto Y, Yamashita S. Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. Bio Factors. 1999;9:241–6.Google Scholar
  17. 17.
    Iwamoto Y, Yamagami T, Folkers K, Blomqvist CG. Deficiency of coenzyme Q10 in hypertensive rats and reduction of deficiency by treatment with coenzyme Q10. Biochem Biophys Res Commun. 1974;58:743–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, et al. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens. 2009;27:1863–72.CrossRefPubMedGoogle Scholar
  19. 19.
    Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2009;4:CD007435.Google Scholar
  20. 20.
    Aberg F, Appelkvist EL, Dallner G, Ernster L. Distribution and redox state of ubiquinones in rat and human tissues. Arch Biochem Biophys. 1992;295:230–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Kawarazaki H, Ando K, Nagae A, Fujita M, Matsui H, Fujita T. Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats. Nephrol Dial Transplant; 2010 (in press).Google Scholar
  22. 22.
    Kido M, Ando K, Onozato ML, Tojo A, Yoshikawa M, Ogita T, et al. Protective effect of dietary potassium against the vascular injury in salt-sensitive hypertension. Hypertension. 2008;51:225–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Gregg D, Rauscher FM, Goldschmidt-Clermont PJ. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am J Physiol Cell Physiol. 2003;285:C723–34.PubMedGoogle Scholar
  24. 24.
    Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension. 2000;36:142–6.PubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2010

Authors and Affiliations

  • Akira Ishikawa
    • 1
  • Hiroo Kawarazaki
    • 2
  • Katsuyuki Ando
    • 2
  • Megumi Fujita
    • 2
  • Toshiro Fujita
    • 2
  • Yukio Homma
    • 1
  1. 1.Department of Urology, Graduate School of MedicineThe University of TokyoTokyoJapan
  2. 2.Department of Nephrology and Endocrinology, Graduate School of MedicineThe University of TokyoTokyoJapan

Personalised recommendations